

Thermo Fisher launches next-generation platform of Gibco CTS Detachable Dynabeads

06 September 2023 | News

Breakthrough platform delivers process flexibility and scalability with the first active release mechanism of its kind for clinical trial and commercial manufacturing use



American firm Thermo Fisher Scientific Inc. has announced the launch of Gibco CTS Detachable Dynabeads (CTS Detachable Dynabeads), its next-generation platform of Dynabeads with the first active release mechanism of its kind for clinical trial and commercial manufacturing use.

The active release mechanism of CTS Detachable Dynabeads utilises a release buffer that helps enable users to actively detach Dynabeads from a target cell at any point during their manufacturing process. As a result, CTS Detachable Dynabeads help drive manufacturing cost savings while delivering high cell purity, yield and viability. These manufacturing benefits can help cell therapy developers get more life-changing treatments to patients faster, especially for those diagnosed with complex diseases such as blood cancers.

CTS Detachable Dynabeads offer process flexibility, compatibility with automation, and scalability through its differentiating active release mechanism. This functionality, for cGMP and clinical use, helps empower users to achieve greater control of their process with the ability to consistently deliver target cells with the desired characteristics for their therapy. Cell recovery, phenotype, and viability for downstream steps within the workflow are also optimized through this platform. These advantages are critical for cell therapy manufacturers who need to scale their manufacturing while maintaining consistent performance as they transition from process development to clinical trials and commercial manufacturing.